Daniel O Connor, MD
Orthopaedic Surgery · Elmhurst, NYNPI 1114960523
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,400 of the $3,203 with a category attached, or 74.9%. 12 manufacturers reported payments, led by Sequoia Surgical, Inc. at 37.5% of the total. Reporting peaked in 2021 at $1,256 and has fallen 53.4% since, to $585 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in NY, where the typical reported total is $4,024.
Across 37 payments — averaging $86.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sequoia Surgical, Inc.$1K
- Gotham Surgical Solutions & Devices, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$527
- Zimmer Biomet$96
- Vertex$39
- Medacta USA, Inc.$33
- plus $109 from 6 others
What the payments were for
- Food & beverage$80325%
- Education$2,40075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sequoia Surgical, Inc. | 1 | $1,200 |
| Gotham Surgical Solutions & Devices, Inc. | 1 | $1,200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $527 |
| Zimmer Biomet | 1 | $96 |
| Vertex | 2 | $39 |
| Medacta USA, Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Orthofix Medical, Inc. | 1 | $20 |
| Bioventus LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| KCI USA, Inc. | 1 | $14 |
How this compares
$3,203 in reported general payments places this provider in the 45th percentile of 1,079 orthopaedic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium ErDiclofenac Sodium | 54 | $1,403 |
| Diclofenac Sodium | 134 | $1,281 |
| Meloxicam | 74 | $137 |
| Celecoxib | 11 | $132 |
| Tramadol Hcl | 21 | $53 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Elmhurst
- Anthony RomeoNew York$26.8M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$13.2M
- William RicciNew York$11.6M
- Steven HaasNew York$11.3M
- Giles ScuderiNew York$10.7M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.